Document is current
Any future updates will be listed below
-
Authors
Manzano-Muñoz, Albert
Yeste, José https://orcid.org/0000-0001-7540-7305
Ortega, María A.
Martín, Fernando https://orcid.org/0000-0002-3496-9093
López, Anna
Rosell, Jordi
Castro, Sandra https://orcid.org/0000-0001-8518-749X
Serrano, César
Samitier, Josep
Ramón-Azcón, Javier https://orcid.org/0000-0002-3636-8013
Montero, Joan https://orcid.org/0000-0002-9192-4836
- License Information
-
More Information
Article History
Received: 14 July 2022
Accepted: 8 November 2022
First Online: 1 December 2022
Competing interests
: J.M. is co-inventor of dynamic BH3 profiling (developed by the Letai laboratory and patented by Dana-Faber Cancer Institute) and has received royalties, was a paid consultant for Oncoheroes Biosciences and Vivid Biosciences, is an unpaid board member for The Society for Functional Precision Medicine, and he is currently collaborating with AstraZeneca. C.S. has received research funding (institution) from Karyopharm, Pfizer Inc, Deciphera Pharmaceuticals, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals and Blueprint Medicines; payment for lectures from Deciphera Pharmaceuticals, PharmaMar, Bayer AG and Blueprint Medicines; and travel grants from PharmaMar, Pfizer, Bayer AG, Novartis, and Lilly. J.R.-A. and M.A.O. are co-founders of Vitala Technologies and have stocks in the company; J.R.-A. is a Scientific Board member and M.A.O. is a full-time employee in the company. No other relevant competing interests were disclosed by the other authors.
